Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine J Kane, G Honigfeld, J Singer, H Meltzer Archives of general psychiatry 45 (9), 789-796, 1988 | 5650 | 1988 |
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression G Rajkowska, JJ Miguel-Hidalgo, J Wei, G Dilley, SD Pittman, HY Meltzer, ... Biological psychiatry 45 (9), 1085-1098, 1999 | 1966 | 1999 |
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. HY Meltzer, S Matsubara, JC Lee Journal of Pharmacology and Experimental Therapeutics 251 (1), 238-246, 1989 | 1801 | 1989 |
Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT) HY Meltzer, L Alphs, AI Green, AC Altamura, R Anand, A Bertoldi, ... Archives of general psychiatry 60 (1), 82-91, 2003 | 1753 | 2003 |
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia … JP McEvoy, JM Meyer, DC Goff, HA Nasrallah, SM Davis, L Sullivan, ... Schizophrenia research 80 (1), 19-32, 2005 | 1650 | 2005 |
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia HY Meltzer, SR McGurk Schizophrenia bulletin 25 (2), 233-256, 1999 | 1489 | 1999 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial RSE Keefe, RM Bilder, SM Davis, PD Harvey, BW Palmer, JM Gold, ... Archives of general psychiatry 64 (6), 633-647, 2007 | 1455 | 2007 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment JP McEvoy, JA Lieberman, TS Stroup, SM Davis, HY Meltzer, ... American Journal of Psychiatry 163 (4), 600-610, 2006 | 1273 | 2006 |
The dopamine hypothesis of schizophrenia: a review. HY Meltzer, SM Stahl Schizophrenia bulletin 2 (1), 19, 1976 | 1224 | 1976 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs WK Kroeze, SJ Hufeisen, BA Popadak, SM Renock, SA Steinberg, ... Neuropsychopharmacology 28 (3), 519-526, 2003 | 1074 | 2003 |
Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology OD Howes, R McCutcheon, O Agid, A De Bartolomeis, NJM Van Beveren, ... American Journal of Psychiatry 174 (3), 216-229, 2017 | 1027 | 2017 |
The role of serotonin in antipsychotic drug action HY Meltzer Neuropsychopharmacology 21 (2), 106S-115S, 1999 | 1018 | 1999 |
Serotonin receptors: their key role in drugs to treat schizophrenia HY Meltzer, Z Li, Y Kaneda, J Ichikawa Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (7), 1159-1172, 2003 | 1015 | 2003 |
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors BL Roth, SC Craigo, MS Choudhary, A Uluer, FJ Monsma Jr, Y Shen, ... Journal of Pharmacology and Experimental Therapeutics 268 (3), 1403-1410, 1994 | 943 | 1994 |
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia HY Meltzer Psychopharmacology 99, S18-S27, 1989 | 898 | 1989 |
Cellular changes in the postmortem hippocampus in major depression CA Stockmeier, GJ Mahajan, LC Konick, JC Overholser, GJ Jurjus, ... Biological psychiatry 56 (9), 640-650, 2004 | 890 | 2004 |
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression M Maes, HY Meltzer, E Bosmans, R Bergmans, E Vandoolaeghe, ... Journal of affective disorders 34 (4), 301-309, 1995 | 838 | 1995 |
A novel augmentation strategy for treating resistant major depression RC Shelton, GD Tollefson, M Tohen, S Stahl, KS Gannon, TG Jacobs, ... American Journal of Psychiatry 158 (1), 131-134, 2001 | 834 | 2001 |
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia ND Woodward, SE Purdon, HY Meltzer, DH Zald International Journal of Neuropsychopharmacology 8 (3), 457-472, 2005 | 821 | 2005 |
Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. HY Meltzer, G Okayli The American journal of psychiatry 152 (2), 183-190, 1995 | 694 | 1995 |